{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:33:29Z","timestamp":1788449609106,"version":"build-2803163510"},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T00:00:00Z","timestamp":1143763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The purpose of the current study was to determine the toxicity and response of a fixed dose intracerebrospinal fluid (CSF) etoposide in the treatment of patients with newly diagnosed neoplastic meningitis (NM). NM reportedly occurs in 1% to 5% of patients with known cancer. Currently available treatment options are limited and provide only modest benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty\u2010seven patients (median age, 55 yrs) with clinically and cytologically documented NM received intra\u2010CSF etoposide. Tumor histologies included lung (8 patients), breast (5 patients), primary brain tumor (4 patients), non\u2010Hodgkin lymphoma (4 patients), melanoma (4 patients), colon (1 patient), and prostate (1 patient). Concurrent involved\u2010field radiotherapy (19 of 27 patients) or systemic chemotherapy (17 of 27 patients) was administered based on clinical indications. Etoposide was administered at a fixed dose (0.5 mg every day given 5 days per week every other week for 8 weeks [induction]). Patients were evaluated by CSF cytology and neurologic examination at the conclusion of induction therapy. Responding patients continued to receive etoposide (5 consecutive days every 4 weeks) with monthly evaluations.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Seven of 27 patients (26%) treated with etoposide had a cytologic response and either stable or improved neurologic status at the conclusion of induction. Eight patients (30%) developed disease progression during induction therapy and did not complete the 8\u2010week induction course of therapy. At the conclusion of induction therapy, 12 patients (44%) had persistently positive CSF cytology, although they were clinically stable. In responding patients, time to neurologic disease progression ranged from 8 weeks to 40 weeks (median, 20 wks). Toxicity manifested as transient chemical arachnoiditis (5 of 27 patients; 13% of all treatment cycles). The 6\u2010month neurologic disease progression\u2010free survival was 11%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Etoposide appears to have modest activity against NM and easily managed toxicity. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21828","type":"journal-article","created":{"date-parts":[[2006,3,31]],"date-time":"2006-03-31T17:46:46Z","timestamp":1143827206000},"page":"2021-2027","source":"Crossref","is-referenced-by-count":68,"title":["Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis"],"prefix":"10.1002","volume":"106","author":[{"given":"Marc C.","family":"Chamberlain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denice D.","family":"Tsao\u2010Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Groshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,31]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550070064013"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1994.00540170033013"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8619(18)30252-4"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.561"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1200\/JCO.1987.5.10.1655","article-title":"A prospective randomized trial of single\u2010agent versus combination chemotherapy in meningeal carcinomatosis","volume":"5","author":"Hitchens R","year":"1987","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.10.3110"},{"key":"e_1_2_5_8_2","first-page":"3394","article-title":"A randomized trial comparing intrathecal sustained\u2010release ara\u2010C (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors","volume":"11","author":"Glantz M","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.1993.11.10.1978","article-title":"Involved field radiotherapy and intra\u2010Ommaya methotrexate\/ara\u2010C in patients with AIDS\u2010related lymphomatous meningitis","volume":"11","author":"Chamberlain M","year":"1993","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00254052"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197610)38:4<1471::AID-CNCR2820380404>3.0.CO;2-0"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197507242930402"},{"key":"e_1_2_5_13_2","first-page":"6101","article-title":"Pharmacokinetics of intra\u2010ventricular and intravenous N, N', N\u201c\u2010triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans","volume":"46","author":"Strong J","year":"1986","journal-title":"Cancer Res."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.11.1765"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950615)75:12<2919::AID-CNCR2820751220>3.0.CO;2-9"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90404-1"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02228887"},{"key":"e_1_2_5_18_2","first-page":"2017","article-title":"High\u2010dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland S","year":"1987","journal-title":"J Oncol."},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.9.546"},{"key":"e_1_2_5_20_2","first-page":"211","article-title":"Pharmacology of intrathecal VP\u201016\u2010213 in dogs","volume":"12","author":"Savaraj N","year":"1992","journal-title":"J Neurooncol."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685957"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1841"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025633704071"},{"key":"e_1_2_5_24_2","first-page":"63","article-title":"Tolerability of long\u2010term intraventricular etoposide therapy with high cumulative doses in pediatric brain tumor patients","volume":"4","author":"Slavc I","year":"2003","journal-title":"Neurooncology.."},{"key":"e_1_2_5_25_2","first-page":"114","volume-title":"Survival analysis","author":"Miller RG","year":"1981"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21828","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21828","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:27:40Z","timestamp":1760268460000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,31]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1002\/cncr.21828"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21828","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,31]]}}}